Page 75 - MEMOCiberer014-ENG

Most relevant scientific articles
• sauceDo-cueVas, laura p., isabel ruppen, pilar ximénez-embún, samuel DominGo, JaVier Gayarre, JaVier muñoz, Jose m. silVa, maría J. García, anD JaVier benítez. CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response . Oncotarget 5, no . 8 (2014): 2330 .
• osorio, ana, roGer l. milne, Karoline KucHenbaecKer, tereza VacloVá, Guillermo pita, rosario alonso, paolo peterlonGo et al . DNA glycosylases involved in Base Excision Repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers . PLoS Genetics 10, no . 4 (2014): e1004256 .
• KamieniaK, marta m., Daniel rico, roGer l. milne, iVan muñoz-repeto, Kristina ibáñez, miGuel a. Grillo, samuel DominGo et al . Deletion at 6q24 . 2–26 predicts longer survival of high-grade serous epithelial ovarian cancer patients . Molecular oncology 9, no . 2 (2015): 422-436 .
• manciKoVa, VeroniKa, raquel buJ, esmeralDa castelblanco, lucía inGlaDa-pérez, anna Diez, aGuirre a. cubas, maria curras-Freixes et al . DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival . International Journal of Cancer 135, no . 3 (2014): 598-610
• apellániz-ruiz, m., l. inGlaDa-pérez, m. e. G. naranJo, l. sáncHez, V. manciKoVa, m. currás-Freixes, a. a. de Cubas et al . High frequency and founder effect of the CYP3A4* 20 loss-of-function allele in the Spa- nish population classifies CYP3A4 as a polymorphic enzyme . The pharmacogenomics Journal (2014) .
Highlights
Institution: Fundación Centro Nacional de Investigaciones Oncológicas Contact: Fundación Centro Nacional de Investigaciones Oncológicas C/ Melchor Fernández Almagro, 3 . 28029 Madrid · Phone: (+34) 91 224 69 65 / 91 732 80 00
Projects. The Unit 706 obtained more tan 2M euros of funding from competitive projects that were ongoing in 2014 . It is worthy to note that people funded by CIBERER participate as research team in 25% of projects .
Regarding with agreements with Pharma industry, in 2014 we had two ongoing projects (with CELGE- NE and Pfizer), which aims were to characterize nab-paclitaxel neurotoxicity, and to identify microRNA predictors of response to TKIs in clear cell renal cell carcinoma .
In addition, we participated in 3 intra-CIBERER initiatives, one of them acting as Coordinator .
Results. Research performed during 2014 led to: 1- identification of new susceptibility genes related to breast cancer and phenotype modulators, 2- identification of por prognosis predictors on rare diseases, 3- establish the prevalence and the effect of genetic alterations in new genes related to neuroendocri- ne tumours develoment, and 4- identificatio of variants in drug metabolizing enzymes associated with treatment response prediction . Our activity in 2014 has led to the identification of two new major sus- ceptibility genes, which will be published in high impact factor journal in 2015 .
Technology transfer. In 2014 we have provided services based on arrays and other high-throughput platforms to clinical groups, hospitals and Universities . The consultancy on Familial Cancer dealt with 250 patients referred by other hospitals and centers in Spain .
Clinical transfer. The U-706 has continued to participate in the development of clinical guidelines . In 2014, in the production of the Bannayan-Riley-Ruvalcaba syndrome Guide .
Training and visibility. We organized three training courses (one of them international), and an Inter- national Symposium on rare diseases . Two of them were co-financed by CIBERER . As in previous years, the training activity of the Group on rare diseases culminated with obtaining the degree of doctor by 3 students .
www .ciberer .es 75